WELL Health Announces Results for Q4 and Full Year 2024 Reflecting Record Annual Revenue
WELL achieved annual revenue of $919.7 million in 2024, an increase of 19% compared to the prior year. Under applicable...
Clinical Trial
US Clinical Communication & Collaboration Market worth US$1.57 billion by 2029 with 13.5% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., April 14, 2025 /PRNewswire/ -- The US Clinical Communication & Collaboration Market is expected to reach US$1.57 billion by...
Sidekick Health Cracks the Code on Medication Adherence — Driving Better Outcomes and Lower Costs
NEW YORK, April 14, 2025 /PRNewswire/ -- Medication non-adherence is a significant and preventable challenge in healthcare, contributing to an...
Promino Nutritional Sciences Inc. Launches Second Preclinical Study Targeting Reduction of Muscle Loss in Breast and Prostate Cancer Patients Undergoing Chemotherapy
Research to explore Promino's patented amino acid blend in addressing treatment-related muscle wasting in two of the most prevalent cancers...
VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma
— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to...
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April...
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document...
NanoVibronix Regains Nasdaq Compliance
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today...
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with...
Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company...
GenomOncology Announces BioMCP: Open Source Model Context Protocol (MCP) for Biomedical AI Assistants and Agents
CLEVELAND, April 10, 2025 /PRNewswire/ -- GenomOncology today announced BioMCP, a new open-source technology that helps artificial intelligence (AI) systems...
Over 53 Million Myeloma Milestones Shared During 2025 Myeloma Action Month
Myeloma Action Month Global Campaign Celebrates Resilience, Strengthens Connections, and Inspires Hope in 52 Countries WorldwideSTUDIO CITY, Calif., April 10,...
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple...
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60...
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s...
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the...
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Evaxion to present at World Vaccine Congress
Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)...
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over...
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and...